Highly potent compounds serve an increasingly significant role in numerous R&D landscapes and pharmaceutical intensive medical treatments; i.e. oncology, atrial fibrillation, osteoporosis. In order to produce these products, a thorough process of product risk analysis is required in order to maintain a consistent manufacturing balance between production scale, market distribution and demand requirements. As a key step to utilize this new suite, Frontida’s manufacturing assessments will verify each highly potent compound’s level of toxicity, potential personnel and facility exposure limitations.
BlogAugust 19, 2020
Frontida BioPharm, Inc. Announces Highly Potent Compound Contract Manufacturing Suite to Support Existing Product Development and Manufacturing Capabilities